Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Anxiety During Caries Removal Using Chemo-mechanical Versus Conventional Methods

NCT07344415 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-12-31
Last updated
2026-01-15

Condition(s) studied

Caries Active

Investigational drug(s) / intervention(s)

CariemoveDrilling using bur

Cariemove: It is a newly introduced Egyptian product. It consists of a transparent liquid containing 0.5% sodium hypochlorite, 0.1 M mixtures of three amino acids, leucine, lysine and glutamic acid.

Drilling using bur: Rotary dental burs using high speed hand piece under water spray cooling system

Study summary

This study aims to clinically assess this newly introduced Egyptian chemo-mechanical caries removal gel versus conventional drilling method . The concept of preserving healthy tooth structures and employing atraumatic restorative techniques during cavity preparation aligns with the principles of minimally invasive dentistry. This approach prioritizes patient comfort, reassurance, and fosters a positive perception of dental treatment.

Eligibility

Sex
ALL
Min age
10 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: 1. Open carious lesions with dentin involvement, but not involving the pulp in lower molars. 2. The access of the carious lesion has to be large enough to allow the penetration of the excavator. 3. Asymptomatic vital teeth, without clinical evidence of pulp, furcation, or periapical pathology. 4. Patients who sign informed consent. 5. Co-operative patients approving to participate in the trial. Exclusion Criteria: 1. Patients with spontaneous or elicited pain from caries. 2. Patients with systemic diseases. 3. Presence of intraoral/extraoral swellings. 4. Deep dental caries involving pulp. 5. Presence of swelling/fistula in relation to carious tooth. 6. Inability to return for recall visits. 7. Patients with bad oral hygiene 8. Refuse to participate in the study.

Primary outcome measure(s)

  • Level of anxiety and discomfort — Baseline (Day 1)
    Visual Analogue Scale from 0 to 10 (0 represents no pain and 10 represents the worst pain)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry Cairo University Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07344415 on ClinicalTrials.gov ↗ ← All trials in Egypt